Filing Flows › Arcadia Biosciences (RKDA) › Q2 2025
Arcadia Biosciences (RKDA) Q2 2025 earnings results (second quarter 2025)
10-Q filed Aug 14, 2025
Arcadia Biosciences (RKDA) reported revenue of $1.5M for the second quarter 2025 (Q2 2025), +11% from a year earlier and +21% from the quarter before. Operating margin was -34.4%, net loss $4.5M (306.4% of revenue).
Arcadia Biosciences, Q2 2025: revenue $1.5M (+11% year over year), operating margin -34.4%, net loss $4.5M, operating cash flow −$2.0M. The chart follows the revenue to costs, profit and cash.
| Q2 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $1.5M | +21% | +11% |
| Operating profit | −$501K | -195% | — |
| Net earnings | −$4.5M | -272% | — |
| Operating cash flow | −$2.0M | — | — |
What changed
Revenue was $1.5M in Q2 2025, up 11% year over year and up 21% from the previous quarter.
Operating costs exceeded revenue by $501K, an operating margin of -34.4%. The quarter ended with a net loss of $4.5M, after a profit of $2.6M the previous quarter. Net interest and other expense of $4.0M was the main reason.
Operating cash flow was −$2.0M. Non-cash charges added back $15K of depreciation and $86K of share-based compensation. Working capital and other items added $2.3M.
Questions
What was Arcadia Biosciences' revenue in the second quarter 2025?
Arcadia Biosciences (RKDA) reported revenue of $1.5M for the second quarter 2025 (Q2 2025), +11% from a year earlier and +21% from the quarter before.
Was Arcadia Biosciences profitable in the second quarter 2025?
Operating loss was $501K (-34.4% of revenue) and net loss $4.5M.